Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).
Status:
Recruiting
Trial end date:
2028-11-15
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2a, open-label, non-randomized, multi-dose study of mirdametinib
monotherapy in adults with NF1 and cNF.
In both Phases of the study, participation in the study will comprise three periods:
screening, treatment and post-study safety follow-up to be performed at the NF1 and cNF
specialty center: Johns Hopkins University.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Johns Hopkins University
Collaborator:
Neurofibromatosis Therapeutic Acceleration Program